[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 1990

The Effect of an Intralesional Sustained-Release Formulation of Interferon Alfa-2b on Basal Cell Carcinomas

Author Affiliations

From the University of Arizona College of Medicine, Tucson (Drs Edwards and Perednia); the University of Texas Medical School, Houston (Dr Tucker); and Schering-Plough Research, Kenilworth, NJ (Drs Smiles, Tanner, and Peets and Mr Taylor). Dr Smiles is now with Oclassen Pharmaceuticals Inc, San Rafael, Calif.

Arch Dermatol. 1990;126(8):1029-1032. doi:10.1001/archderm.1990.01670320053006
Abstract

• Intralesional interferon alfa-2b has been proven effective in the treatment of basal cell carcinomas. Because nine injections over a 3-week period have been necessary to produce clinically significant cure rates, a sustainedrelease protamine zinc chelate interferon formulation has been developed. In this study, 65 basal cell carcinomas were treated in one of two dosing schedules with intralesional sustained release interferon alfa-2b (10 million IU per injection). Thirty-three patients received a single injection and 32 patients received one injection per week for 3 weeks. At study week 16, 80% of evaluable tumors treated with three injections and 52% treated with one injection were cured histologically. Two patients discontinued injections because of side effects. A sustainedrelease protamine zinc preparation of interferon alfa-2b shows promise as a practical, effective, and cosmetically elegant treatment for basal cell carcinoma.

(Arch Dermatol. 1990;126:1029-1032)

×